These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 14522142)

  • 1. Alpha-synuclein oligomerization: a role for lipids?
    Welch K; Yuan J
    Trends Neurosci; 2003 Oct; 26(10):517-9. PubMed ID: 14522142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.
    Sharon R; Bar-Joseph I; Frosch MP; Walsh DM; Hamilton JA; Selkoe DJ
    Neuron; 2003 Feb; 37(4):583-95. PubMed ID: 12597857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease.
    Hegde ML; Jagannatha Rao KS
    Arch Biochem Biophys; 2003 Oct; 418(2):169-78. PubMed ID: 14522588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.
    Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease?
    Lee SJ
    Antioxid Redox Signal; 2003 Jun; 5(3):337-48. PubMed ID: 12880487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease?
    Rajagopalan S; Andersen JK
    Mech Ageing Dev; 2001 Sep; 122(14):1499-510. PubMed ID: 11511392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein.
    Arawaka S; Saito Y; Murayama S; Mori H
    Neurology; 1998 Sep; 51(3):887-9. PubMed ID: 9748051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper(II)-induced self-oligomerization of alpha-synuclein.
    Paik SR; Shin HJ; Lee JH; Chang CS; Kim J
    Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):821-8. PubMed ID: 10359669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic effects of alpha-synuclein aggregation.
    Lundvig D; Lindersson E; Jensen PH
    Brain Res Mol Brain Res; 2005 Mar; 134(1):3-17. PubMed ID: 15790525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.
    Uversky VN
    J Biomol Struct Dyn; 2003 Oct; 21(2):211-34. PubMed ID: 12956606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
    Krüger R; Müller T; Riess O
    J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein aggregation.
    Bodles AM; Irvine GB
    Protein Pept Lett; 2004 Jun; 11(3):271-9. PubMed ID: 15182228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments.
    Cole NB; Murphy DD; Lebowitz J; Di Noto L; Levine RL; Nussbaum RL
    J Biol Chem; 2005 Mar; 280(10):9678-90. PubMed ID: 15615715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
    Fujiwara H; Hasegawa M; Dohmae N; Kawashima A; Masliah E; Goldberg MS; Shen J; Takio K; Iwatsubo T
    Nat Cell Biol; 2002 Feb; 4(2):160-4. PubMed ID: 11813001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
    Shtilerman MD; Ding TT; Lansbury PT
    Biochemistry; 2002 Mar; 41(12):3855-60. PubMed ID: 11900526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
    Dev KK; Hofele K; Barbieri S; Buchman VL; van der Putten H
    Neuropharmacology; 2003 Jul; 45(1):14-44. PubMed ID: 12814657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-synuclein: normal function and role in neurodegenerative diseases.
    Norris EH; Giasson BI; Lee VM
    Curr Top Dev Biol; 2004; 60():17-54. PubMed ID: 15094295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
    Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.